Related Experiment Video
Updated: May 16, 2026
07:38
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
c-Myc and E2F1 drive PBK/TOPK expression in high-grade malignant lymphomas.
Fang Hu1, Ronald B Gartenhaus, Xianfeng F Zhao
1Marlene and Stewart Greenebaum Cancer Center and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Leukemia Research
|December 15, 2012
Summary
The study identifies a new signaling pathway involving c-Myc, E2F1, and PBK (also known as TOPK) that drives high-grade lymphoma growth. Inhibiting this pathway shows promise for developing new cancer treatments.
Area of Science:
- Oncology
- Molecular Biology
- Hematology
Background:
- The c-Myc oncogene is frequently implicated in hematologic malignancies, such as Burkitt's lymphoma.
- Targeting c-Myc-driven pathways offers potential therapeutic strategies for cancer, necessitating identification of key downstream effectors.
Purpose of the Study:
- To investigate the role of serine-threonine kinase PBK/TOPK in high-grade lymphomas.
- To elucidate the regulatory relationship between c-Myc, E2F1, and PBK/TOPK in lymphoma pathogenesis.
Main Methods:
- Analysis of PBK/TOPK expression in high-grade lymphomas.
- Correlation studies between PBK/TOPK, c-Myc, and E2F1 expression levels.
- Experimental inhibition of c-Myc, E2F1, and PBK/TOPK to assess effects on cell growth and survival.
Main Results:
- PBK/TOPK is frequently overexpressed in high-grade lymphomas.
- PBK/TOPK expression positively correlates with c-Myc and E2F1 levels.
- c-Myc regulates PBK/TOPK expression via E2F1.
- Inhibition of c-Myc, E2F1, or PBK/TOPK similarly reduced lymphoma cell growth and survival.
Conclusions:
- A c-Myc-E2F1-PBK/TOPK signaling pathway is identified in high-grade lymphomas.
- This pathway represents a potential therapeutic target for novel antineoplastic treatments.
Related Concept Videos
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
01:06Induced Pluripotent Stem Cells
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Somatic cells are...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:23Master Transcription Regulators
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...